Cargando…
Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829198/ https://www.ncbi.nlm.nih.gov/pubmed/33505983 http://dx.doi.org/10.3389/fnut.2020.613928 |
_version_ | 1783641136421666816 |
---|---|
author | Ceccarelli, Giancarlo Borrazzo, Cristian Pinacchio, Claudia Santinelli, Letizia Innocenti, Giuseppe Pietro Cavallari, Eugenio Nelson Celani, Luigi Marazzato, Massimiliano Alessandri, Francesco Ruberto, Franco Pugliese, Francesco Venditti, Mario Mastroianni, Claudio M. d'Ettorre, Gabriella |
author_facet | Ceccarelli, Giancarlo Borrazzo, Cristian Pinacchio, Claudia Santinelli, Letizia Innocenti, Giuseppe Pietro Cavallari, Eugenio Nelson Celani, Luigi Marazzato, Massimiliano Alessandri, Francesco Ruberto, Franco Pugliese, Francesco Venditti, Mario Mastroianni, Claudio M. d'Ettorre, Gabriella |
author_sort | Ceccarelli, Giancarlo |
collection | PubMed |
description | Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy. Methods: This retrospective, observational cohort study included 200 adults with severe COVID-19 pneumonia. All patients received therapeutic regimens including low molecular weight heparin plus one or more between hydroxychloroquine, azithromycin, antivirals, and Tocilizumab. Oral bacteriotherapy was used as complementary treatment. Results: Out of the 200 patients, 112 received BAT without oral bacteriotherapy, and 88 BAT with oral bacteriotherapy. Crude mortality was 22%. Eleven percent died in the group of patients treated with BAT plus oral bacteriotherapy vs. 30% subjects in the group of patients managed only with BAT (p < 0.001). By multivariate analysis, the age >65 years, CRP >41.8 mg/L, Platelets <150.000 mmc, and cardiovascular events were associated with the increased risk of mortality. Oral bacteriotherapy was an independent variable associated with a reduced risk for death. Despite large prospective trials are needed, this study highlights a possible role for oral bacteriotherapy in the management of patients hospitalized for COVID-19 pneumonia. |
format | Online Article Text |
id | pubmed-7829198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78291982021-01-26 Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study Ceccarelli, Giancarlo Borrazzo, Cristian Pinacchio, Claudia Santinelli, Letizia Innocenti, Giuseppe Pietro Cavallari, Eugenio Nelson Celani, Luigi Marazzato, Massimiliano Alessandri, Francesco Ruberto, Franco Pugliese, Francesco Venditti, Mario Mastroianni, Claudio M. d'Ettorre, Gabriella Front Nutr Nutrition Background: Mounting evidence suggests SARS-CoV-2 may impact on host microbiota and gut inflammation, infecting intestinal epithelial cells. This possible link and its implications can be investigated by observing the effects of modulation of the microbial flora in patients with COVID-19. The aim of this study was to compare the rate of mortality, the need of ICU hospitalization and the length of hospitalization in patients with severe COVID-19 pneumonia who received the best available therapy (BAT) vs. patients treated with BAT and supplemented with oral bacteriotherapy. Methods: This retrospective, observational cohort study included 200 adults with severe COVID-19 pneumonia. All patients received therapeutic regimens including low molecular weight heparin plus one or more between hydroxychloroquine, azithromycin, antivirals, and Tocilizumab. Oral bacteriotherapy was used as complementary treatment. Results: Out of the 200 patients, 112 received BAT without oral bacteriotherapy, and 88 BAT with oral bacteriotherapy. Crude mortality was 22%. Eleven percent died in the group of patients treated with BAT plus oral bacteriotherapy vs. 30% subjects in the group of patients managed only with BAT (p < 0.001). By multivariate analysis, the age >65 years, CRP >41.8 mg/L, Platelets <150.000 mmc, and cardiovascular events were associated with the increased risk of mortality. Oral bacteriotherapy was an independent variable associated with a reduced risk for death. Despite large prospective trials are needed, this study highlights a possible role for oral bacteriotherapy in the management of patients hospitalized for COVID-19 pneumonia. Frontiers Media S.A. 2021-01-11 /pmc/articles/PMC7829198/ /pubmed/33505983 http://dx.doi.org/10.3389/fnut.2020.613928 Text en Copyright © 2021 Ceccarelli, Borrazzo, Pinacchio, Santinelli, Innocenti, Cavallari, Celani, Marazzato, Alessandri, Ruberto, Pugliese, Venditti, Mastroianni and d'Ettorre. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Ceccarelli, Giancarlo Borrazzo, Cristian Pinacchio, Claudia Santinelli, Letizia Innocenti, Giuseppe Pietro Cavallari, Eugenio Nelson Celani, Luigi Marazzato, Massimiliano Alessandri, Francesco Ruberto, Franco Pugliese, Francesco Venditti, Mario Mastroianni, Claudio M. d'Ettorre, Gabriella Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title | Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title_full | Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title_fullStr | Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title_full_unstemmed | Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title_short | Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study |
title_sort | oral bacteriotherapy in patients with covid-19: a retrospective cohort study |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829198/ https://www.ncbi.nlm.nih.gov/pubmed/33505983 http://dx.doi.org/10.3389/fnut.2020.613928 |
work_keys_str_mv | AT ceccarelligiancarlo oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT borrazzocristian oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT pinacchioclaudia oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT santinelliletizia oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT innocentigiuseppepietro oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT cavallarieugenionelson oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT celaniluigi oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT marazzatomassimiliano oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT alessandrifrancesco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT rubertofranco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT pugliesefrancesco oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT vendittimario oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT mastroianniclaudiom oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy AT dettorregabriella oralbacteriotherapyinpatientswithcovid19aretrospectivecohortstudy |